Semi-Annual Report — FY2026 H1
What HEALIOS K.K. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-12View the original on EDINET
How much it says
62Detailed
What moved here
24named for the first time
Its own wording
39terms
Which filing this is
37/ 37newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, HEALIOS K.K. primarily advanced preparations for a domestic conditional and time-limited approval application for the ARDS treatment HLCM051, progress on the REVIVE-ARDS trial, and the development of infrastructure for sales of iPSC-related products, including eNK® cells, and conditioned media. At the same time, cash and cash equivalents increased through the issuance of new shares and other measures, while an operating loss was recorded.
Komori's summary of this document, not the document's own words.62Detailed
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
76
Very detailed
61
Detailed
60
Detailed
50
Typical
50
Typical
68
Detailed
55
Typical
69
Detailed
53
Typical
79
Very detailed
50
Typical
R&D spend17億円Money spent making new things.
Cash left over-37億円Cash from the business, less what went into equipment.
Spent on equipmentNot disclosedThis document does not carry the figure.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.